Cargando…
Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
To prevent the development of endocrine-resistant breast cancer, additional targeted therapies are increasingly being trialled in combination with endocrine therapy. The molecular mechanisms facilitating cancer cell survival during endocrine treatment remain unknown but could help direct selection o...
Autores principales: | Madden, Stephen F., Cremona, Mattia, Farrelly, Angela M., Low, Weng Hei, McBryan, Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935392/ https://www.ncbi.nlm.nih.gov/pubmed/36266450 http://dx.doi.org/10.1038/s41417-022-00548-0 |
Ejemplares similares
-
Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023) -
Highlighting Indication of extracorporeal membrane oxygenation in endocrine emergencies
por: Chao, Anne, et al.
Publicado: (2015) -
S100β as a serum marker in endocrine resistant breast cancer
por: Charmsaz, Sara, et al.
Publicado: (2017) -
Tirbanibulin Attenuates Pulmonary Fibrosis by Modulating Src/STAT3 Signaling
por: Wang, Xin, et al.
Publicado: (2021) -
Combined targeting EGFR and SRC as a potential novel therapeutic
approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)